慢加急性肝衰竭中溶血磷脂酰胆碱/自分泌运动因子/溶血磷脂酸轴失调与死亡率和全身炎症相关
ACLF患者血清LPC降低、LPA升高,死亡患者LPC更低(AUC 0.94,P<0.001),ATX升高与疾病严重度和炎症相关。LPA抑制单核细胞MerTK/CD163表达并促进促炎细胞因子产生,该通路可能成为ACLF治疗靶点。
要点
- ACLF患者血清LPC降低、LPA升高,LPC水平与死亡率相关(AUC 0.94)。
- ATX升高与ACLF严重度评分及IL-6、TNF-α相关,肝细胞ATX表达增加。
- LPA抑制单核细胞MerTK/CD163表达并促进促炎因子产生,不增加吞噬能力。
核心结论
- ACLF中ATX上调促进LPC向LPA转化,LPA抑制单核细胞MerTK/CD163表达并增加促炎细胞因子产生,该代谢通路或可用于重编程单核细胞治疗。
研究设计与样本
- 健康志愿者及脓毒症或急性肝衰竭患者作为对照,通过免疫组化检测肝脏ATX表达。
主要发现
- ACLF患者血清LPC降低、LPA水平上调,死亡患者LPC水平低于存活者(AUC 0.94,P<0.001)。
- 高级别ACLF患者LPC浓度最低,且在入院前3天升高;ATX浓度在AD和ACLF患者中更高,与MELD、CLIF-SOFA及LPC/LPA浓度相关。
- LPC降低与单核细胞MerTK和CD163表达升高相关;血浆ATX浓度与IL-6和TNF-α相关,并与肝细胞ATX表达增加相关。
- ACLF患者单核细胞HLA-DR低于对照、CD163/MerTK高于对照;体外LPA(而非LPC)处理降低ACLF患者CD163/MerTK表达。
- LPA诱导CD14+细胞促炎细胞因子上调,但不增加吞噬能力。
临床怎么用
- LPC水平(AUC 0.94)可能作为ACLF死亡风险的候选生物标志物,ATX/LPA轴或为治疗靶点。
- LPA依赖的单核细胞活化提示干预该代谢通路可能调节ACLF全身炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is characterized by systemic inflammation, monocyte dysfunction, and susceptibility to infection. Lysophosphatidylcholines (LPCs) are immune-active lipids whose metabolic regulation and effect on monocyte function in ACLF is open for study. APPROACHES & RESULTS: Three hundred forty-two subjects were recruited and characterized for blood lipid, cytokines, phospholipase (PLA), and autotaxin (ATX) concentration. Peripheral blood mononuclear cells and CD14+ monocytes were cultured with LPC, or its autotaxin (ATX)-derived product, lysophosphatidic acid (LPA), with or without lipopolysaccharide stimulation and assessed for surface marker phenotype, cytokines production, ATX and LPA-receptor expression, and phagocytosis. Hepatic ATX expression was determined by immunohistochemistry. Healthy volunteers and patients with sepsis or acute liver failure served as controls. ACLF serum was depleted in LPCs with up-regulated LPA levels. Patients who died had lower LPC levels than survivors (area under the receiver operating characteristic curve, 0.94; P < 0.001). Patients with high-grade ACLF had the lowest LPC concentrations and these rose over the first 3 days of admission. ATX concentrations were higher in patients with AD and ACLF and correlated with Model for End-Stage Liver Disease, Consortium on Chronic Liver Failure-Sequential Organ Failure Assessment, and LPC/LPA concentrations. Reduction in LPC correlated with higher monocyte Mer-tyrosine-kinase (MerTK) and CD163 expression. Plasma ATX concentrations rose dynamically during ACLF evolution, correlating with IL-6 and TNF-α, and were associated with increased hepatocyte ATX expression. ACLF patients had lower human leukocyte antigen-DR isotype and higher CD163/MerTK monocyte expression than controls; both CD163/MerTK expression levels were reduced in ACLF ex vivo following LPA, but not LPC, treatment. LPA induced up-regulation of proinflammatory cytokines by CD14+ cells without increasing phagocytic capacity. CONCLUSIONS: ATX up-regulation in ACLF promotes LPA production from LPC. LPA suppresses MerTK/CD163 expression and increases monocyte proinflammatory cytokine production. This metabolic pathway could be investigated to therapeutically reprogram monocytes in ACLF.
引用
- Trovato FM, Zia R, Napoli S, et al. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation. Hepatology. 2021. PMID: 33908067. doi:10.1002/hep.31738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。